Neurocrine Biosciences (NBIX) Tops Q2 EPS by 50c
Tweet
Share
E-mail
Get Alerts NBIX Hot Sheet
Price: $170.00 +0.88%
Revenue Growth %: +27.0%
Financial Fact:
Research and development: 20.94M
Today's EPS Names:
DTGI, OCCI, MAYS, More
Revenue Growth %: +27.0%
Financial Fact:
Research and development: 20.94M
Today's EPS Names:
DTGI, OCCI, MAYS, More
Join SI Premium – FREE
Neurocrine Biosciences (NASDAQ: NBIX) reported Q2 EPS of $1.63, $0.50 better than the analyst estimate of $1.13. Revenue for the quarter came in at $580 million versus the consensus estimate of $547.1 million.
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Concentrix Corporation (CNXC) Misses Q2 EPS by 1c; Guides lower than expectations
- Activist Ed Garden lauds new Fortune Brands CEO - Bloomberg
- SanDisk (SNDK) PT Raised to $3,000 at Bernstein SocGen Group, 'We believe this is not understood by the Street'
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
